about
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple MyelomaMaintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer PatientsA Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast CancerStudy of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic LeiomyosarcomaPhase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin LymphomaChidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma PatientsAdjuvant Palbociclib in Elderly Patients With Breast CancerTrial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal CancersAtezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast CancerResistant Ovarian Cancer, Olaparib and Liposomal DoxorubicinFIL Study on ABVD DD-DI as Upfront Therapy in HL.Combination Chemotherapy in Treating Patients Undergoing Surgery for Newly Diagnosed High-Grade OsteosarcomaRituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin LymphomaTrial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast CancerEfficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder CancerTherapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With AvastinPhase II Study of Valproate and Doxorubicin in Malignant MesotheliomaA Phase I/II Trial of VR-CHOP in Lymphoma PatientsMaintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM)Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) PatientsTAC Versus TC for Adjuvant Breast CancerA Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell LymphomaA Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast CancerStudy of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian CancerPhase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas.R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell LymphomaGenes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic CancerDoxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By SurgeryCombination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma Who Are Undergoing Surgery With or Without Autologous Bone Marrow or Peripheral Stem Cell TransplantCombination Chemotherapy and Radiation Therapy in Treating Young Patients With Hodgkin's LymphomaDocetaxel, Doxorubicin, and Prednisone in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone TherapyRadiation Therapy or Combination Chemotherapy in Treating Young Patients With Hodgkin's LymphomaIntensified IAA With PBPC Support in Breast Tumors With Evidence of a HRDPilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast CancerBevacizumab and Doxorubicin Hydrochloride Liposome in Treating Women With Locally Recurrent or Metastatic Breast CancerPhase 2 Study of Rituximab-ABVD in Classical Hodgkin LymphomaAlternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple MyelomaTherapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer
P4844
Q61864815-4F311B79-A2D5-40B7-85AC-B211FCB58889Q61865294-541F870E-CA62-47A5-98D8-105FB96BE8AFQ61894319-EF27D12C-3191-40F4-99D1-BC0DFB7DD5E7Q61894321-CF1F573A-4A02-4DCB-86FC-0FD617B74979Q61902861-30D52A01-B3C0-416D-98C7-6847518C38EAQ61904758-F5FE8BE6-23D1-4C95-AD1D-9E7FCBB79C5EQ61906992-E49628F1-124C-4F33-A744-E3FED6C6B486Q61907382-FCF0D430-4994-43AE-B6D9-750AFC588E57Q61908846-4B5A5269-4187-4409-A960-5CD715D63F4BQ61909224-DB13DBD5-54F5-4447-A7D4-D4187546B968Q61909322-7BF6AECE-1D99-48ED-A98D-8B409E99C183Q61914409-B4673095-2B52-4097-9F92-178EF0177C63Q61915196-90A8C9E9-B7F4-47F9-B305-1AB7271EF236Q61915329-1934CF19-58C8-4E02-81E8-77BAB693EEA1Q61915378-43492CB5-EB66-41F8-95AC-E73B193C048FQ61915385-00418206-301D-4DF1-9D84-551D75C8D1B6Q61915445-DBF0858B-D72A-46F2-91D3-65EAD47248E4Q61915533-AC68DB47-C780-4AC3-9756-5D37EA06EECEQ61915537-C5F607AF-0EF0-4079-82C5-FF246A26EEE7Q61915593-E83962D2-46A1-4F1E-950C-FECFC25C77D3Q61917641-A4315EEF-8D65-4B12-9767-279FCE6DBF4CQ61917760-902FC287-D451-4797-8CB5-F914F62AB771Q61918397-7A162A4C-6F8F-4AAF-A191-5D8C26ABBD97Q61918404-DAB7E046-4AD4-4787-8DC3-4F3710FD48B6Q61918600-DA82E47C-4FFA-431C-89E8-8673ACF0261EQ61918607-65D61740-1FB0-4B2E-A472-582A87838AA8Q61921040-AFB26CA1-5C88-4323-9741-690F35B45447Q61921076-3FB39FB0-4835-4E89-AF99-F9E32BE3AE53Q61921457-FB0CDBA1-558D-44E6-9486-076329A9F7E6Q61921622-FFD127E5-187F-4AD9-AF7C-77FE3246872FQ61922326-50422D61-C9F1-42D5-A8F4-8E88DC493210Q61922359-A0842DC5-5A23-4824-BB5A-5D158A57C69AQ61922386-9A208B30-3191-4E72-A3D4-C19A449BB0E3Q61922398-BB34F23B-F2C7-46E9-BE4B-FF48C7749B43Q61923859-23E6EF14-E742-437D-BF53-BE15901EBC41Q61924479-52ACDB7A-447F-4237-92E1-1DF2C0A7D139Q61924621-3E86061C-66B3-42F9-B5DC-8E75F3D0FA76Q61933490-1550F88B-DD8E-46E5-A98F-5E5C2B555BB0Q61934208-9CC4ABE7-BA72-4088-8A43-CE2917FB3CC5Q61934343-4CBA5352-35D9-43A8-B741-D6846952EF8C
P4844
description
pharmaceutical product
@en
name
Caelyx
@en
سيليكس
@ar
type
label
Caelyx
@en
سيليكس
@ar
altLabel
Liposomal Doxorubicin
@en
prefLabel
Caelyx
@en
سيليكس
@ar
P4044
P3637
EMEA/H/C/000089